OncoTargets and Therapy (Sep 2017)

Current advances of long non-coding RNA highly upregulated in liver cancer in human tumors

  • Ma Z,
  • Huang H,
  • Xu Y,
  • He X,
  • Wang J,
  • Hui B,
  • Ji H,
  • Zhou J,
  • Wang K

Journal volume & issue
Vol. Volume 10
pp. 4711 – 4717

Abstract

Read online

Zhonghua Ma,1,2,* Hesuyuan Huang,3,* Yetao Xu,4 Xuezhi He,5 Jirong Wang,2 Bingqing Hui,1,2 Hao Ji,1,2 Jing Zhou,1,2 Keming Wang1,2 1The Second Clinical Medical College, 2Department of Oncology, Second Affiliated Hospital, 3Department of Cardiothoracic Surgery, Children’s Hospital, 4Department of Obstetrics and Gynecology, First Affiliated Hospital, 5Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China *These authors contributed equally to this work Abstract: Long non-coding RNAs (lncRNAs) are a group of non-coding RNAs (ncRNAs) >200 nucleotides in length that govern diverse biological processes. Recent evidence suggests that lncRNAs are involved in cancer cell proliferation, apoptosis, invasion, migration, and metastasis. Dysregulation of lncRNAs has been observed in various tumors, and lncRNAs act as oncogenes or tumor suppressors in these malignancies. It has been revealed that lncRNA highly upregulated in liver cancer (HULC) is tightly correlated with a number of cancers such as hepatocellular carcinoma, gastric cancer, colorectal cancer, osteosarcoma, and diffuse large B-cell lymphoma. Depletion of HULC suppressed cancer cell proliferation, migration, and invasion and induced apoptosis. Additionally, HULC may function as a diagnostic biomarker and prognostic indicator for some tumors. In this review, we summarize the current knowledge of the role of HULC in cancer progression and the clinical management of human cancers. Keywords: lncRNA, HULC, cancer

Keywords